ArticleJournal of feline medicine and surgery2026
Clinical trial of molnupiravir with or without an oral immune stimulant as a first-line treatment of feline infectious peritonitis.
Article in Journal of feline medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sustained clinical remission and long-term safety of molnupiravir as first-line therapy for effusive feline infectious peritonitis: a 40-week retrospective study.Veterinary and animal science · 2026Article
- Epidemiological and Clinical Insights from 68 Veterinarian-Reported Cases of Feline Infectious Peritonitis During the Documented FIP Epizootic in Cyprus.Pathogens (Basel, Switzerland) · 2026Article
- Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines.Viruses · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesThe aim of the present study was to evaluate the efficacy of oral molnupiravir (MPV; EIDD-2801) in cats with naturally occurring feline infectious peritonitis (FIP), with a subset of cats being administered a known immune stimulant (liposome-toll-like receptor agonist complex [LTC] orally.MethodsA prospective, open-label longitudinal single-center clinical trial was conducted. Cats with FIP were enrolled and treated with oral MPV (10-21 mg/kg PO q12h) for 84 days. A subset of cats (41 cats with effusive FIP) was randomized to concurrently be administered the oral immune stimulant. Cats were evaluated at 0, 4, 8 and 12 weeks followed by a 12-week observation period.ResultsA total of 73 cats were included in the study and 77% of the cats survived to 6 months. The median total bilirubin concentrations were significantly different (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.